PredictImmune

PredictImmune developed the first validated prognostic biomarker test—PredictSURE IBD™—to predict long-term outcomes in newly diagnosed patients with inflammatory bowel disease. The company’s technology enables personalized therapy by identifying patients likely to experience aggressive versus mild disease courses. Clinical studies have demonstrated its utility in guiding treatment decisions at diagnosis. The company has expanded its commercial presence across Europe and the US, with plans to develop similar tests for other autoimmune diseases such as systemic lupus erythematosus. As of early 2024, it was actively expanding its product portfolio but has since entered liquidation proceedings.